The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2022 | Risk stratification & treatment of multiple myeloma precursor conditions
Francesco Maura, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, comments on the limitations of current systems used to predict progression from precursor conditions to multiple myeloma, and discusses questions related to the treatment of patients with these precursor conditions. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
